安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- JCI - Welcome
In this issue of the JCI, Spencer et al used a TNF-driven mouse model of small intestinal Crohn’s disease to identify a specific bacterial pathobiont, Chlamydia muridarum, as a necessary and sufficient driver of region-restricted inflammation
- JCI - About the Journal of Clinical Investigation
Email staff@the-jci org or call 734-222-6050 To avoid confusion regarding correspondence, inquiries, and decisions, the JCI will typically communicate only with the responsible party corresponding author of submissions
- JCI - Welcome
Copyright © 2026 American Society for Clinical Investigation ISSN: 0021-9738 (print), 1558-8238 (online)
- JCI - Author Information Center
The JCI considers research submissions in the following categories [Top of page] Click the category name for formatting instructions; or go to How to submit your manuscript for the first time (new windows) Research manuscripts provide substantial new mechanistic insights into biology and disease using preclinical models as well as materials and data derived from humans These manuscripts are
- JCI - Welcome
Liver invasion is one of the most frequent events in the progression of gallbladder cancer (GBC) However, the cellular and pathological role of the tumor-liver–interface microenvironment in liver invasion is still enigmatic Here, we applied single-cell and spatial transcriptomics to systematically investigate the cellular component and gene expression regulation of the microenvironment
- JCI - The science of safety: adverse effects of GLP-1 receptor agonists . . .
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
- JCI - Submission instructions - first
Submit a manuscript directly to the JCI through your account on the JCI’s submission website Follow the instructions to either register for an account or access your existing account Click the button below to open the submission site Submit a manuscript to the JCI and JCI Insight simultaneously using the Dual-Journal Submission option
- JCI - The gut microbiome and cancer response to immune checkpoint . . .
The field of the microbiome and immunotherapy has skyrocketed since 2015 when two studies demonstrated a fascinating phenomenon in mice: certain gut bacteria could enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in tumors outside of the gut (1, 2) ICIs are a type of cancer immunotherapy in which antibodies that block ICI molecules reinvigorate immune cells to mount a robust
|
|
|